GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

Share

Regulated Information - Denominator

Atlas Special Opportunities, LLChas converted 12convertible bonds in Oxurion resulting in a EUR 300,000capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.

Leuven, BELGIUM,Boston, MA, USMarch 31, 202307.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 28,942,629 new ordinary shares on March 28, 2023, for a total amount of EUR 300,000, as the result of the conversion of 12 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 632,659,186 outstanding ordinary shares carrying voting rights (compared to 603,716,557 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
78,206,161.32
  • Total number of securities with voting rights (all ordinary shares)
632,659,186
  • Total number of ordinary shares (= denominator)
632,659,186
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
  • 694,000 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 694,000 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 976,874 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 976,874 securities carrying voting rights (all ordinary shares);
  • 534,688 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 534,688 securities carrying voting rights (all ordinary shares);
  • 582,248 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 582,248 securities carrying voting rights (all ordinary shares);
  • 92 convertible bonds issued on March 14, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Mary T. Conway
mtconway@conwaycommsir.com





ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com



1Press release Oxurion, 02/03/2023

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Brookfield Corporation Completes Annual Filings19.3.2024 01:55:08 CET | Press release

BROOKFIELD, NEWS, March 18, 2024 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has filed its 2023 annual materials on Form 40-F, including its audited financial statements and management’s discussion and analysis for the year ended December 31, 2023, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR. These documents are also available at www.brookfield.com and a hardcopy will be provided to shareholders free of charge upon request. About Brookfield Corporation Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have one of the largest pools of discretionary capital globally, which is deployed across our three core businesses – asset management, insurance solutions, and our operating businesses. Through our core businesses, we invest in real assets that form the backbone of the global economy to deliver

Schneider Electric Collaborates with NVIDIA on Designs for AI Data Centers18.3.2024 23:12:33 CET | Press release

• New reference designs will offer a robust framework for implementing NVIDIA’s accelerated computing platform within data centers;• Designs will optimize performance, scalability, and energy efficiency; Schneider Electric, the leader in the digital transformation of energy management and automation, today announced a collaboration with NVIDIA to optimize data center infrastructure and pave the way for groundbreaking advancements in edge artificial intelligence (AI) and digital twin technologies. Schneider Electric will leverage its expertise in data center infrastructure and NVIDIA’s advanced AI technologies to introduce the first publicly available AI data center reference designs. These designs are set to redefine the benchmarks for AI deployment and operation within data center ecosystems, marking a significant milestone in the industry's evolution. With AI applications gaining traction across industries, while also demanding more resources than traditional computing, the need for

Hexagon Purus ASA: Issue of shares under the Company's LTIP plan18.3.2024 21:35:00 CET | Press release

The long term incentive plan of December 2020 (the "2020 LTIP") for Hexagon Purus ASA (the "Company") vested upon approval of the 2023 annual financial statements. Consequently, the Company's board of directors, has resolved to issue in total 909,742 new shares to the entitled employees pursuant to the authorization to issue shares granted on 25 May 2023. Following registration of the share issue, the Company's registered share capital will be NOK 27,770,719.80, divided into 277,709,198 shares, each having a face value of NOK 0.10. 541,242 of the new shares were issues to PDMRs, as further specified in the attached forms. For additional information, please contact: Salman Alam, Chief Financial Officer, Hexagon Purus Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com Mathias Meidell, Investor Relations Director, Hexagon Purus Telephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com About Hexagon Purus: Hexagon Purus enables zero emission mobility for a cleaner energy future. T

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D18.3.2024 21:00:00 CET | Press release

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid metabolism, as well as hepatic steatosis.Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.Treatment with lanifibranor alone and in combination with empagliflozin decreased the ratio of visceral abdominal fat to subcutaneous fat, reflecting a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue.The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.Inventiva will host an

Driving Excellence: C.K. McWhorter Grants Bentley Motors McWhorter Family Trust Warrant of Automotive Distinction18.3.2024 20:56:28 CET | Press release

LONDON, March 18, 2024 (GLOBE NEWSWIRE) -- The McWhorter Family Trust proudly announces its partnership with Bentley Motors, heralding a new era of automotive excellence. In a momentous decision, the Trust bestows upon Bentley Motors the emblem of automotive distinction, recognizing its unwavering commitment to luxury, innovation, and craftsmanship. Incorporating Bentley Motors into the McWhorter Family Trust’s Portfolio: The addition of Bentley Motors to the McWhorter Family Trust’s prestigious portfolio signifies a strategic expansion into the realm of automotive luxury. This pivotal decision underscores the Trust's dedication to investing in brands that epitomize excellence and timeless sophistication. Furthermore, it opens doors to potential indirect investment opportunities in Bentley Motors through avenues such as automotive technology and events. Strategic Investment Approach of C.K. McWhorter: C.K. McWhorter, in orchestrating the structure of a Single Family Office (SFO), strat

HiddenA line styled icon from Orion Icon Library.Eye